Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

A former head of the US Food and Drug Administration cut his body fat in half using GLP-1 drugs. In his book, he compares the ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight ... dosages slightly different from the standard, FDA-approved amounts or including additives such as vitamins ...